- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06549920
Danish Breast Cancer Group Internal Mammary Node Study (DBCG IMN)
August 8, 2024 updated by: Birgitte Offersen, Danish Breast Cancer Cooperative Group
The DBCG IMN study is a nationwide prospective population-based cohort study allocating node-positive breast cancer patients with right-sided tumors to internal mammary node irradiation (IMNI) and patients with left-sided tumors to no IMNI.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
7630
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with macrometastatic node-positive breast cancer treated with loco-regional radiotherapy.
Exclusion Criteria:
- Prior malignancies, bilateral breast cancer, neoadjuvant systemic therapy, recurrence before radiotherapy, and non-standard radiotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Internal mammary node irradiation
Patients with right-sided breast cancer tumors were allocated to internal mammary node irradiation.
|
Irradiation of the internal mammary nodes in intercostal space 1-4.
Other Names:
|
|
No Intervention: No internal mammary node irradiation
Patients with left-sided breast cancer tumors were allocated to no internal mammary node irradiation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 15-years.
|
Censored at end of study or by emigration.
|
15-years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breast cancer mortality
Time Frame: 15-years.
|
Censored at end of study or by emigration.
|
15-years.
|
|
Distant recurrences
Time Frame: 15-years.
|
Censored at end of study or by emigration.
Death by any cause was regarded as competing event.
|
15-years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2003
Primary Completion (Actual)
November 17, 2023
Study Completion (Estimated)
January 1, 2034
Study Registration Dates
First Submitted
August 8, 2024
First Submitted That Met QC Criteria
August 8, 2024
First Posted (Actual)
August 12, 2024
Study Record Updates
Last Update Posted (Actual)
August 12, 2024
Last Update Submitted That Met QC Criteria
August 8, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DBCG IMN protocol
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data may be requested at the DBCG RT committee and the DBCG board.
IPD Sharing Time Frame
Undecided.
IPD Sharing Access Criteria
DBCG board.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Internal mammary node irradiation
-
Yonsei UniversityActive, not recruitingBreast NeoplasmsKorea, Republic of
-
Fujian Medical University Union HospitalRecruiting
-
Cancer Institute and Hospital, Chinese Academy...Zhejiang Cancer Hospital; Jiangsu Province Hospital of Traditional Chinese... and other collaboratorsActive, not recruiting
-
Samsung Medical CenterRecruitingBreast Cancer Stage IIIKorea, Republic of
-
Shandong Cancer Hospital and InstituteHenan Cancer Hospital; The Affiliated Hospital of Qingdao UniversityUnknown
-
Rigshospitalet, DenmarkLundbeck Foundation; Danish Heart Foundation; Copenhagen Hospital CorporationUnknownAngina Pectoris | Ischemic Heart Disease | Coronary ArteriosclerosisDenmark
-
Shandong Cancer Hospital and InstituteCompleted
-
Sheffield Teaching Hospitals NHS Foundation Trust3MCompletedCardiac Event | Complication of Coronary Artery Bypass Graft | Coronary Bypass Graft Stenosis | Arrest; Cardiac, Complicating SurgeryUnited Kingdom
-
Shandong Cancer Hospital and InstituteCompleted
-
Ottawa Heart Institute Research CorporationPopulation Health Research InstituteNot yet recruiting